-
Hindawi Publishing CorporationISRN Organic ChemistryVolume 2013, Article ID 292396, 14 pageshttp://dx.doi.org/10.1155/2013/292396
Review ArticleGoniomitine: An Overview on the Chemistry ofThis Indole Alkaloid
José C. F. Alves
Instituto de Pesquisas de Produtos Naturais Walter Mors, Centro de Ciências da Saúde, Bloco H,Universidade Federal do Rio de Janeiro, 21941-902 Rio de Janeiro, RJ, Brazil
Correspondence should be addressed to José C. F. Alves; [email protected]
Received 20 September 2013; Accepted 22 October 2013
Academic Editors: G. Li, F. Machetti, and J. Wu
Copyright © 2013 José C. F. Alves. This is an open access article distributed under the Creative Commons Attribution License,which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This paper reports an overview on the chemistry of the indole alkaloid goniomitine focusing, mainly, on the methods of synthesisrelated to this natural product and analogs.
1. Introduction
The indole alkaloids belong to the class of natural substancesdisplaying biological activities as well as a broad structuraldiversity. In view of these important properties, these prod-ucts are target of study in the areas of isolation, identification,and synthesis [1–5]. Goniomitine (1) (Figure 1) is an indolealkaloid that was isolated and identified by Randriambolaet al. [6] and Hashimoto and Husson [7]. The uniquestructure and biological activity of goniomitine have attractedthe attention of several groups. This review describes theisolation, biogenesis hypothesis, chemical transformations,and syntheses of this alkaloid and analogs.
2. Isolation of Goniomitine
In the course of studies of the alkaloids of the genusGonioma, Randriambola et al. [6] isolated, from the rootbark of Gonioma malagasy, a crystalline compound namedgoniomitine with melting point of 150∘C (ether-methanol),[𝛼]D20
−80∘ (c 0.9 in CHCl3), and molecular formula
C19H26N2O (HRMS, M+∙ 298.2080, calculated for 298.2045).
The structure of goniomitine was initially proposed as indi-cated in Figure 1, with 20S, 21R configuration, based on itsNMR spectra. Its absolute structure was deduced through thecorrelation with other alkaloids from Aspidosperma found in
the same plant from where goniomitine had been isolated.The relative structure of goniomitine (1) was soon after con-firmed by Takano et al. [8] through the total enantioselectivesynthesis of the natural form of this alkaloid. It could beevidenced that the absolute structure of the compound 1 isenantiomeric to the one that had been initially proposed for20S, 21R configuration.
3. Biogenesis of Goniomitine
Randriambola et al. [6] proposed that goniomitine (1) may bederived from the Aspidosperma skeleton of vincadifformine(2) by the successive steps depicted in Scheme 1.
4. Chemical Transformations andSyntheses of Goniomitine and Analogs
4.1. Chemical Transformations of Goniomitine. For the occa-sion of the structural determination of goniomitine (1) [6],this compound was transformed into the N-acetyl derivative5 upon treatment with Ac
2O in MeOH and into the N,O-
diacetyl derivative 6 upon treatment with Ac2O in pyridine
(Scheme 2). The formation of the acetylated compounds 5and 6 confirmed the presence of the groups OH and NH inthe structure of 1.
-
2 ISRN Organic Chemistry
OH
N
N
H
H
S21
R20
OH
N
N
H
H
S21R
20
(unnatural)(20S, 21R)-(+)-Goniomitine (1)
(natural)(20R, 21S)-(−)-Goniomitine (1)
Figure 1: Natural (−)- and unnatural (+)-goniomitine (1).
c
d
NH
N
H
1 2
34
56
789
10
1112
13
1415
1617 18
192021
CO2Me
a-b
N
N
H
H
HHO
+ NH
NHHO +
N
NH
H
+
OH
N
NH
H
12
34
56
78910
1112
13
14
15
16
17 181920
21
OH
1
2 3 44
Scheme 1: Biogenetic hypothesis of transformation of vincadifformine (2) into goniomitine (1): (a) oxidative fission of the C-5, N-4 bond; (b)decarboxylation; (c) retro-Mannich reaction; (d) nucleophilic attack of the indole nitrogen on the iminium moiety.
N
NHH
OH
N
NH
OH
Ac
Ac2O Ac2OMeOH Py
N
NH
Ac
OAc
15 6
Scheme 2: Chemical transformations of goniomitine (1) into the acetyl derivatives 5 and 6.
-
ISRN Organic Chemistry 3
NH
N
NH
N
NH
N
NH
N
I
a b c d
e
N H
CH3
TMS
(55%) (57%)
OH
(97%)
OH OH
(91%)
Me Me
(59%)
+
−
N
NH
OH
Me
+
(36 : 23)
(+/−)-12
7 8 9 10 11
11
Scheme 3: Reagents and conditions: (a) (i) n-BuLi (2.2 equiv), hexane (reflux, 6 h) and (ii) methyl 3-(3-pyridyl)propanoate, THF (−78 to15∘C); (b) MeMgI (10 equiv), ethylene oxide (10 equiv), Et
2
O (1 h), reflux (2 h); (c) MeI, CH2
Cl2
(reflux, 2 h); (d) H2
, PtO2
, MeOH (3 h); (e)H2
, PtO2
, NaOMe, MeOH (3 h).
4.2. Synthesis of the Goniomitine Analog (+/−)-12. In orderto ascertain unambiguously the unprecedented structure ofthe alkaloid goniomitine (1), Hashimoto and Husson [7]synthesized the goniomitine analog (+/−)-12 by the sequenceof reactions depicted in Scheme 3.
4.3. Total Synthesis of (−)-Goniomitine by Takano. The firstenantiocontrolled total synthesis of natural (−)-goniomitine(1) was published in 1991 by Takano et al. [8], who estab-lished the absolute stereochemistry of this alkaloid. Thistotal synthesis, depicted in Scheme 4, starts with the chiralcyclopentadienone synthon (−)-13.
4.4.The First Biomimetic Approach to the Skeleton of Goniomi-tine from an Aspidosperma Alkaloid. The results from thestudy of biomimetic transformation of an Aspidospermaalkaloid (2) into the substances 39-40, with the skeletonof goniomitine (1), were published in 1995 by Lewin et al.[9]. The sequences of reactions for the discovery of a newbiomimetic in vitro rearrangement are depicted in Scheme 5.Scheme 6 displays the proposed mechanism [9] for thetransformation of compound 36 into the alkaloids 39 and40.
4.5. Semisynthesis of (+)-(16S,20S,21R)-16-Hydroxymethyl-goniomitine from (−)-Vincadifformine. In continuation tothe studies of chemical transformations of vincadifformine(2) into alkaloids analogs to goniomitine (1), Lewin andSchaeffer [10] published in 1995 the semisynthesis of (+)-16-hydroxymethyl-goniomitine (45).This alkaloid was obtained
as a result of the attempts to synthesize (+)-goniomitine(1) from the compound 40, previously obtained from (−)-vincadifformine (2) (Scheme 5) [9]. In Scheme 7 are depictedthe sequences of reactions that led to the synthesis of com-pound 45 as well as other alkaloids with tetracyclic skeletonof goniomitine (1).
4.6. Synthesis of the Goniomitine Analogs 52–55 by Cycload-dition Reactions. In the year 1996, Gürtler et al. [11] pub-lished the synthesis of the goniomitine analogs 52–55 by[4 + 2] cycloaddition reactions between 2-vinylindolesand substituted cyclic enamines, via anodic oxidation(Scheme 8).
4.7. Proposal of Synthesis of Goniomitine by Alves. In the year2000, Alves [12] presented his qualification exam of doctorateabout a plan of synthesis of the indole alkaloid goniomitine(1). The convergent strategies and synthetic routes for thesynthesis of this alkaloid, idealized on that occasion, aredescribed in the supplementary material of this review,available online at http://dx.doi.org/10.1155/2013/292396.
4.8. Syntheses of Cytotoxic Bisindole Alkaloids. In the year2000, Lewin et al. [13] published an article about a slightmod-ification of the Borch reductive amination method (delayedaddition of NaBH
3CN) [14, 15], applied to compound 40,
analog of the natural alkaloid goniomitine (1). As a result ofthis reaction, a series of new cytotoxic bisindole alkaloids wasprepared, as depicted in Scheme 9.
-
4 ISRN Organic Chemistry
O
HH
O
HH O OS
S
O
SS
O
HO
O
d
i
NH
O
I
NH
O
N
O
NH
O
N
O
NH
H
O
NH
N NH
m
t
u
21
z
y
NH
O NH
O
N
NH
O
q
l
a-c(53%)
(−)-13
e-f
g-h (75%)
MeOMeOMeO j-k
OEt
OEt
(81%)
CO2Me
(81%)
OMe
(11 : 70)
+
n-p
NH2
HN
HN
HNHN
HN HN HN
r-s
CN
CN CN
Cl − +
v-x
OH
(82%)31: C21-H𝛽(−)-1: C21-H𝛼
15 16
171819
21 2322
24
28 29 30
27 26 25
14
20
(82% ⇒ 17)
(78% ⇒ 25) (65% ⇒ 23)
(84% ⇒ 27) (40% ⇒ 29)
(72% ⇒ 14)
Scheme 4: Reagents and conditions: (a) Zn (5.0 equiv), AcOH-EtOH (1 : 3), reflux (4 h); (b) EtI (2.0 equiv), t-BuOK (1.2 equiv), THF (−70 to−30∘C, 15min); (c) allyl bromide (2.0 equiv), t-BuOK (1.2 equiv), THF (−30∘C, 5min); (d) o-dichlorobenzene (reflux, 24 h); (e) LiAlH
4
(1.0equiv), CuI (0.5 equiv), HMPA-THF (1 : 4), −75∘C (15min); (f) propane-1,3-diyldithiotosylate (1.5 equiv), t-BuOK (3.0 equiv), t-BuOH-THF(1 : 4), 0∘C; (g) KOH (5.0 equiv), t-BuOH (70∘C, 12 h); (h) CH
2
N2
, Et2
O; (i) MeI (1.0 equiv), CaCO3
(5.0 equiv), 10% aq. MeCN (reflux, 1 h);(j) Ph
3
P (4.0 equiv), CBr4
(2.0 equiv), Et3
N (3.0 equiv), CH2
Cl2
(0∘C, 5min); (k) LDA (3.0 equiv), THF (−78∘C, 10min); (l) compound 20 (1.1equiv), PdCl
2
(PPh3
)2
(2%), CuI (5%), Et3
N (reflux, 30min); (m) NaOEt (10 equiv), Et3
N (5%), EtOH (reflux, 3 h); (n) (i) dicyclohexylborane(1.5 equiv), THF (0∘C, 30min), (ii) 10% NaOH (1.0 equiv), 30% H
2
O2
(3.0 equiv), 0∘C (30min); (o) phthalimide (1.3 equiv), Ph3
P (1.3 equiv),(i-PrO
2
CN)2
(1.3 equiv), THF (0∘C, 10min); (p) NH2
NH2
⋅H2
O (4.0 equiv), EtOH (reflux, 2 h); (q) [Me2
N=CH2
]Cl (1.5 equiv), CH2
Cl2
(r.t.,30min); (r) MeI, MeOH (r.t., 10min); (s) NaCN (1.3 equiv), DMF (100∘C, 10min); (t) POCl
3
(6.0 equiv), toluene (reflux, 2 h); (u) NaBH4
,MeOH, 0∘C; (v) DIBAL (1.5 equiv), CH
2
Cl2
(−75∘C, 10min); (x) dil. H2
SO4
; (y) NaBH4
; (z) 30% HCl-MeOH (1 : 10), reflux (30min).
-
ISRN Organic Chemistry 5
N
N
H
OO
O
N
N
H
OO
O
N
N
H
N
N
H
O
N
N
Cl Cl Cl
ClCl
H
N
NH
O
NH
N
H
OO
O
N
N
H
O
N
NH
NH
N
H
5 5
55b
a
5
c
5
d
e
f
g
h
CO2Me CO2Me CO2Me CO2Me
CO2MeCO2Me
CO2MeCO2Me
CO2Me
3 steps
MeO
(82%)
+ Ar
Ar
Ar
Ar = m-Cl-C6H4
(71%)
𝛼35a: C5-H𝛽35b: C5-H (3 : 1)
(100%)
(18%)
HO
HO
HO
(53%)
CHOCHO
+
(42 : 11)
(40%)
(52%)
(48%)
2 32 33 34
36
37
38
40 39
Scheme 5: Reagents and conditions: (a)m-CPBA (1.1 equiv), CH2
Cl2
(r.t., 3 h); (b) 0.2mol L−1 NaOH-MeOH (r.t., 5min); (c) NaI (3.0 equiv),AcOH (r.t., 1.5 h); (d) 11 mol L−1 HCl (105∘C, 10min); (e) TFA (16 equiv), CH
2
Cl2
(r.t., 20min); (f) TFA (r.t., 4 h); (g) TFA (16 equiv), CH2
Cl2
(r.t., 15 h); (h) TFA (12.5 equiv), CH2
Cl2
(r.t., 45 h).
In continuation to the studies of synthesis of cytotoxicbisindole alkaloids, Raoul et al. [16] published, in the year2001, an article with a novel series of these alkaloids pre-pared by reductive amination of the compound 40 withvarious anilines, using the modified Borch amination con-ditions described in Scheme 9 (delayed addition (20min) ofNaBH
3CN) [15]. The influence of substitution of the starting
aniline on the reaction and on cytotoxicity of produceddimers is discussed in the paper.
4.9. Total Synthesis of (+/−)-Goniomitine by Pagenkopf. In theyear 2008, Morales and Pagenkopf [17] published the total
synthesis of racemic (+/−)-goniomitine (1), accomplishedin 17 linear steps with 5.2% overall yield starting fromcommercially available 𝛿-valerolactam (65). Their syntheticapproach includes the application of a formal [3+2] cycload-dition between the highly functionalized nitrile 68 and theactivated cyclopropane 69 to prepare the indole nucleus(Scheme 10).
4.10. Total Synthesis of (+/−)-Goniomitine by Waser. DeSimone et al. [18] published the synthesis of racemic goniomi-tine (1) with the first study of its bioactivity, revealingsignificant cytotoxicity against several cancer cell lines [18,
-
6 ISRN Organic Chemistry
N
N
Cl
O
H TFA
TFA
N
N
Cl Cl
ClHO
OHCH
N
NH
O
N
NOOHC
H
N
NH
O
CHO
CHOCHOCHO
CHO CHO CHO
N
N
H
O
H
N
NH
N
NO
N
NH
O
H N
NH
:
a
b
..
b
a
HO
HO HO
CO2Me CO2Me CO2Me
CO2Me
CO2MeCO2MeCO2Me
CO2Me CO2Me CO2Me
CH2Cl2
+
+
−
−
+−
+
−
+
−
OCOCF3
36
39
36a 36b 36b
36c36d
39a 39b 40
Scheme 6
N
NH
HO
HO
HO
HO
HO
CHO
N
NH
N
NH
H
N
NH
N
NH
N
NH
H
H N
NH
H
a b
c
d e f
CO2Me CO2Me
(62%)
OH OH
OHOHOHOH
OH OH OH
(43%)
CO2H
CH3
(75%)(66%)(35%)
(57%)
40 41 42
43 44 45 46
Scheme 7: Reagents and conditions: (a) NaBH3
CN, AcOH (r.t., 1.5 h); (b) NaOH-MeOH (120∘C, 1 h); (c) LiAlH4
(excess), THF (reflux, 3 h);(d) H
2
(1 atm), 10% Pd-C, MeOH (r.t., 5 h); (e) TiCl3
-H2
O, MeOH (r.t., 20 h); (f) 30% HCl-MeOH (120∘C, 1.5 h).
-
ISRN Organic Chemistry 7
N
NH
CN
CNMe
H
OEt
N
NHH
N
Me
Me
NH
CN
HNH
CN
N
Me
Me
Me
Me
Me N
CN
CN
CN
H
a
b
c
d
N
CO2Me
R2
R1 R3(62%)
+(68%)
49: R2 = H, R3 = CN50: R2 = H, R3 = CO2Me51: R2 = Me, R3 = CO2Me
(53%)
(91%)
47: R1 = Me48: R1 = (CH2)2OEt
CO2Me
55
52
53
54
Scheme 8: Reagents and conditions: (a) vinylindole 47 (1.0 equiv), enamine 49 (2.37 equiv), CH3
CN, LiClO4
(0.1mol L−1), electrolysis(480mV versusAg/AgNO
3
, current (20 to 2mA), 200min); (b) vinylindole 48 (1.0 equiv), enamine 49 (6.17 equiv), CH3
CN, LiClO4
(0.1molL−1), electrolysis (480mV versus Ag/AgNO
3
, current (20 to 2mA), 200min); (c) vinylindole 47 (1.0 equiv), enamine 50 (1.4 equiv), CH3
CN,LiClO
4
(0.1mol L−1), electrolysis (480mV versus Ag/AgNO3
, current (20 to 2mA), 40min); (d) vinylindole 47 (1.0 equiv), enamine 51 (2.1equiv), CH
3
CN, LiClO4
(0.1mol L−1), electrolysis (480mV versus Ag/AgNO3
, current (20 to 2mA), 200min).
19]. The strategy of this synthesis is based on cyclizationof aminocyclopropanes [20], applied to cyclopropyl ketone83 to lead to compound 84 with tetracyclic skeleton ofgoniomitine (Scheme 11).
4.11. Total Syntheses of (+/−)-, (−)-, and (+)-Goniomitine byMukay. In the year 2011, Mizutani et al. [21] published thesyntheses of both racemic and optically active goniomitine,whose principal steps are the preparation of the indole skele-ton by their own developed procedure [22] and alkene cross-metathesis. The synthesis of racemic (+/−)-goniomitine (1)was performed, as a preliminary study, by the sequence ofreactions depicted in Scheme 12.
The convergent total synthesis of the natural (−)-goni-omitine (1) [21] was completed by the sequence of reactionsdepicted in Scheme 13.
Using the synthetic route described in Scheme 13, butstarting from the enantiomer of the lactam 97 (ent-97)Mizu-tani et al. [21] synthesized the unnatural (+)-goniomitine(ent-1).With the racemic, natural, and unnatural goniomitinein hand, the authors [21] executed the preliminary bioactiveassays, which revealed that natural (−)-goniomitine hasstronger antiproliferative activity inMock andMDCK/MDR1cells than its enantiomer.
4.12. Total Synthesis of (+/−)-Goniomitine by Bach. In theyear 2012, Jiao et al. [23] published the total synthesis ofracemic goniomitine (1), using the strategy of C-2 alkyla-tion of indoles catalyzed by palladium via a norbornene-mediated C–H activation [24]. The steps for the synthesisof (+/−)-goniomitine (1), by this strategy, are depicted inScheme 14.
-
8 ISRN Organic Chemistry
N
NH
AcO
HN
HN
HN
HN
HN
NNH
AcO
N
NH
N
NH
NNH
N
NH
H
NNH
H
N
NH
N
NNH
Ac
Ac
Ac
Ac
Ac
N
NH
NN
N
NH
HO
HN
NNH
HO
OH
OH
N
NH
CHO
N
NH
HO
N
NNH
HO
HO
HOHOHO
Me
ab
c
d
ef
g
MeO2C
MeO2C
MeO2C
MeO2CMeO2C
CO2Me CO2Me
CO2Me
CO2Me
CO2MeCO2Me
CO2MeCO2Me
(64%)
MeO2C
(68%)
Ph
+
+
+
(23 : 28)
(51%)(45%)
(38%)(70
%)
(48 : 22)
(32%)
40 56 57
58
58
59
6061
6263
64
NH2 · HCl
Scheme 9: Reagents and conditions: (a) compound 56 (5.0 equiv), NaBH3
CN (immediate addition), MeOH (r.t., 16 h); (b) compound 56 (5.0equiv), NaBH
3
CN (delayed addition, 20min), MeOH (r.t., 16 h); (c) TiCl3
-H2
O (6.0 equiv), MeOH (r.t., 20 h); (d) Ac2
O, Py (r.t., 48 h); (e)Ac2
O, Py (r.t., 3 h); (f) CH2
O, NaBH3
CN, AcOH (r.t., 2 h); (g) LiAlH4
, THF (reflux, 3 h).
-
ISRN Organic Chemistry 9
N
O
NH
NH
O
NH
NH
OCN
N
CN
HN HN HN
H
N
OBn
Bn
BnBn
X
NH
NH
N
O
NH
N
OBn
CN
OMe
NH
NH
N
O
NH
N
O
a
f
g
hi
j j
i
k
l m
2021 21 21
20 20
R 2R1b, c
(82.8%)
(83%) 65: R1 = R2 = H
66: R1 = Et, R2 = Bn
+
d, e(70%) 67: X = OH68: X = CN
CO2Et
CO2Et
CO2Et
(74%)
(98%)
(75%)(97%)
(trace)
(97%)
(70%)
(70%)
(44%)
OH OH
(79%)
(+/−)-Goniomitine (1)
69 70
717225
27 73
29 31
Scheme 10: Reagents and conditions: (a) (i) n-BuLi (2.0 equiv), THF (−78∘C), (ii) EtI (1.0 equiv), −78∘C (1 h), (iii) BnBr (1.0 equiv), r.t.(overnight); (b) (i) LDA (1.0 equiv), THF (−78∘C, 15min), (ii) BrCH
2
CH2
OTHP (1.1 equiv), r.t. (overnight); (c) TsOH (0.1 equiv), MeOH (ice-brine bath, 4 h); (d) Et
3
N (2.1 equiv),MsCl (1.0 equiv), CH2
Cl2
(0∘C to r.t., 3 h); (e) NaCN (2.0 equiv),MeCN, 120∘C (𝜇w, 8 h, 900 rpm stirring);(f) Nitrile 68 (1.0 equiv), cyclopropane 69 (2.9 equiv), TMSOTf (1.0 equiv), EtNO
2
(−30∘C, 24 h); (g) 5% Pd-C (0.03 equiv), mesitylene (reflux,24 h); (h) NaOH (10 equiv), EtOH-H
2
O (1 : 1), 150∘C (𝜇w, 3 h, 900 rpm stirring); (i) Na (5.0 equiv), liq. NH3
(0.042mol L−1), THF (−78∘C,10min); (j) (i) [Me
2
N=CH2
]Cl (1.5 equiv), CH2
Cl2
(r.t., 15min), (ii) MeI (40 equiv), MeOH (r.t., 10min), (iii) NaCN (1.3 equiv), DMF (100∘C,10min); (k) (i) POCl
3
(6.0 equiv), toluene (reflux, 2 h), (ii) NaBH4
(2.0 equiv), MeOH (0∘C, 30min); (l) (i) DIBAL (1.5 equiv), CH2
Cl2
(−78∘C,10min), (ii) 0.75mol L−1 H
2
SO4
, (iii) NaBH4
(2.2 equiv), EtOH (0∘C, 30min); (m) TsOH (cat.), Et3
N-MeOH (3 : 5, v/v), reflux (30min).
4.13. Synthesis of (+)- and (−)-Goniomitine by Lewin. Inthe year 2013, Lewin et al. [25] have published the firstbiomimetic semisynthesis of goniomitine (1), in nine stepswith 11% overall yield, starting from vincadifformine (2).Natural (−)- and unnatural (+)-goniomitine were preparedfrom (+)- and (−)-vincadifformine, respectively.The steps forthe synthesis of unnatural (+)-goniomitine (1) are depicted inScheme 15.
Lewin et al. [25] have synthesized the natural (−)-goni-omitine (1), starting from (+)-vincadifformine (ent-2), using
the same conditions described in Scheme 15. The evaluationof the antiproliferative effect of (+)- and (−)-goniomitine (1),undertaken on five human cancer cell lines, has demonstratedthat unnatural (+)-goniomitine is more potent than itsenantiomer (−)-goniomitine [25], in opposition to Mizutaniet al.’s results on a canine kidney cell line (MDCK II) [21].
4.14. Synthesis of (+/−)-Goniomitine by Zhu. In the year2013, Xu et al. [26] have published a seven-step totalsynthesis of (+/−)-goniomitine (1) through two key steps:
-
10 ISRN Organic Chemistry
N OH
N O N N O N OH N
N
OH
NH
NH
N
NH
O
NH
N
NH
O
N
NH
H
a b c d e
hf g
ij
(67%)
Cbz Cbz Cbz Cbz
CbzCbz
Cbz
(93%) (76%)OEt
(91%)OH
OH
OH
(93%) OMe
Me
(48%)
OTIPSOTIPS
OTIPS OTIPS
COOH
(100%)
(77%) (93%)
H+
74 75 76 77 78 79
80 8281
8384(+/−)-Goniomitine (1)
Scheme 11: Reagents and conditions: (a) (i) n-BuLi (2.2 equiv), THF (0∘C, 30min), (ii) EtI (1.5 equiv), 0∘C (20min), (iii) benzyl chloroformate(1.05 equiv), 0∘C (20min); (b) (i) NaBH
4
(1.05 equiv), MeOH (0∘C, 15min), (ii) conc. H2
SO4
, Et2
O (r.t., 1 h); (c) N2
CH2
COOEt (4.0 equiv),(CuOTf)
2
⋅C7
H8
(0.02 equiv), CH2
Cl2
(18 h); (d) (i) BF3
⋅OEt2
(0.15 equiv), CH2
Cl2
(−20 to 0∘C), (ii) NaOH (9.0 equiv), H2
O-THF-EtOH(1 : 1 : 3), 0∘C to 60∘C (2 h); (e) (i) DMTMM (1.5 equiv), THF (r.t., 60min), (ii) MeNHOMe.HCl (1.0 equiv), NMM (2.0 equiv), r.t. (36 h); (f)TIPSCl (1.05 equiv), imidazole (2.1 equiv), DMF (r.t., 1 h); (g) (i) n-BuLi (1.2 equiv), Et
2
O (0∘C then reflux, 2 h), (ii) CO2
(0∘C, 30min), (iii)H3
O+ (pH 2); (h) (i) t-BuLi (3.0 equiv), compound 82 (1.5 equiv), TMEDA (2.0 equiv), THF (−78∘C, 3 h), (ii) amide 79 (1.0 equiv), THF (0∘C,20min); (i) TsOH (0.2 equiv), CH
2
Cl2
(r.t., 10min); (j) (i) NaBH4
, MeOH (0∘C to r.t., 3 h), (ii) Ac2
O, Py (r.t., overnight), (iii) H2
, Pd-C (0.1equiv), EtOH, (iv) TBAF (4.4 equiv), THF (r.t., 30min).
(i) a novel palladium-catalyzed decarboxylative couplingreaction between the potassium nitrophenyl acetate 118and the vinyl triflate 115 for a rapid production of thefunctionalized cyclopentene 119; (ii) a late-stage construc-tion of the whole tetracyclic scaffold of goniomitine (1)from the functionalized cyclopentene 120 by a one-potintegrated oxidation/reduction/cyclization (IORC) sequence(Scheme 16).
5. Conclusions
In summary, it may be concluded that this brief surveyon the chemistry of goniomitine has covered the literaturerelative to this alkaloid and analogs from 1987 to the firstsemester of the year 2013. Taking into account the resultspublished in this period, a considerable progress on thesynthesis of this alkaloid has been verified in the last years(2008–2013) with the publications of five racemic and twoenantiomeric syntheses. It is also important to emphasize therecent pioneering works on the bioactive assays performedwith the racemic mixtures as well as both enantiomers ofgoniomitine. In spite of these progresses, the development
of new efficient enantioselective synthetic strategies for thisindole alkaloid, with low operational costs, is still a target tobe reached.
Abbreviations
Ac: Acetyl9-BBN: 9-Borabicyclo[3.3.1] nonaneBoc: tert-ButoxycarbonylBn: Benzyln-Bu: n-Butylt-Bu: tert-ButylBz: BenzoylDIAD: Diisopropyl azodicarboxylateDIBAL: Diisobutylaluminum hydrideDMF: N,N-DimethylformamideDMSO: Dimethyl sulfoxideDMTMM: 2,4-Dimethoxy-6-(4-methylmorpholin-4-
ium-4-yl) chlorideDPPA: Diphenylphosphoryl azide
-
ISRN Organic Chemistry 11
H
O
N
O
N
O
NH
N
O
NH
N
O
N
N
NH
R
N
NH
H
a
b.
c
d
e
fg
i
h
j
TBDPSO TBDPSO
TBDPSO
+ OBn
OBn
OBn(84%)
OR
(97%) 87: R = H88: R = Ms
(80%)
(80%)
OTBDPSOTBDPSOTBDPS
OTBDPS
Boc
HO
Bn
BnBnBn
(58%)
+(42%)(97%)
(87%)
(48%) 94: R = Bn95: R = H
(100%)
OH
(+/−)-Goniomitine (1)
85 8689
90
67
919293
n-Bu3Sn
Scheme 12: Reagents and conditions: (a) (i) compound 85 (1.3 equiv), n-BuLi (1.2 equiv), THF (−78∘C, 1.5 h), (ii) compound 86 (1.0 equiv),THF (r.t., 22 h); (b) MsCl (1.6 equiv), Et
3
N (2.0 equiv), CH2
Cl2
(0∘C to r.t., 20min); (c) (i) LDA (2.4 equiv), n-Bu3
SnH (2.4 equiv), THF(−78∘C, 1 h), (ii) CuBr⋅SMe
2
(2.7 equiv), −78∘C (40min), (iii) mesylate 88 (1.0 equiv), THF (−78∘C, 1 h); (d) (i) 2-I-PhNHBoc (1.28 equiv),compound 89 (1.0 equiv), TBAC (3.29 equiv), TFP (0.25 equiv), Pd
2
(dba)3
(0.03 equiv), CuI (0.11 equiv), DMF (r.t., 2 h); (e) (i) o-NO2
PhSeCN(1.54 equiv), n-Bu
3
P (1.55 equiv), THF (r.t., 5 h), (ii) 30% aq. H2
O2
(1.48mol L−1), THF (0∘C (20min), r.t. (17 h)); (f) compound 90 (1.0 equiv),lactam 91 (9.44 equiv), Hoveyda-Grubbs-II cat. (0.3 equiv), neat (140∘C, 3 h); (g) H
2
, 5% Pd-C (0.1 equiv), AcOEt (r.t., 23 h); (h) DIBAL (3.4equiv), THF (−78∘C to r.t.); (i) H
2
, 20% Pd (OH)2
, AcOH-EtOH (5 : 2), r.t. (2 h); (j) TBAF (3.3 equiv), THF (r.t., 14 h).
Et: EthylHMPA: HexamethylphosphoramideLDA: Lithium diisopropylamideLiHMDS: Lithium bis(trimethylsilyl)amidem-CPBA: meta-Chloroperbenzoic acidMe: MethylMs: Mesyl (methanesulfonyl)NMM: N-methylmorpholinePd2(dba)3: Tris(dibenzylideneacetone)dipalladium(0)
i-Pr: iso-Propyln-Pr: n-PropylPh: PhenylPy: PyridineTBAC: Tetrabutylammonium chlorideTBAF: Tetrabutylammonium fluoride
TBDPS: tert-ButyldiphenylsilylTBS: tert-ButyldimethylsilylTf: TrifluoromethanesulfonylTFA: Trifluoroacetic acidTFP: TetrafluorophenylTHF: TetrahydrofuranTHP: TetrahydropyranylTIPSCl: Triisopropylsilyl chloride (chlorotriisopro-
pylsilane)TMEDA: 𝑁,𝑁,𝑁, 𝑁-TetramethylethylenediamineTMSCl: TrimethylsilylchlorideTMSOTf: Trimethylsilyl trifluoromethanesulfonateTs: Tosyl (𝑝-toluenesulfonyl)X-Phos: 2-Dicyclohexylphosphino-2,4,6-
triisopropylbiphenyl.
-
12 ISRN Organic Chemistry
N
O
O PhR
N NH
N
O
O
Ph
NH
N
O
O
Ph
N
NH
H
N
NH
OH
PhN
OH
NH
H
c
d
efg
96: R = CH2CH97: R = CH
a-b(66%)
+
OTBDPS OTBDPS
Boc
90
(65%)
98
(92%)
OTBDPSOTBDPSOTBDPS
99
(62%)
10095
(61%⇒ 100)
(−)-Goniomitine (1)
CH2CH2
Scheme 13: Reagents and conditions: (a) (i) O3
, MeOH (−78∘C, 15min) and (ii) NaBH4
(1.5 equiv), −78∘C to r.t. (2 h); (b) (i) o-NO2
PhSeCN(3.9 equiv), n-Bu
3
P (6.0 equiv), THF (r.t., 3 h) and (ii) 30% aq. H2
O2
, THF (0∘C to r.t., 9 h); (c) indole 90 (1.0 equiv), lactam 97 (3.5 equiv),Hoveyda-Grubbs-II cat. (0.31 equiv), xylene (140∘C, 3 h); (d) H
2
, 5% Pd-C (0.1 equiv), AcOEt (r.t., 27 h); (e) (i) NaH (17.8 equiv), Et2
O (0∘C,30min) and (ii) DIBAL (1.07 equiv), 0∘C to r.t. (10min), repeat three-times; (f) H
2
, 20% Pd (OH)2
, n-PrOH/1,4-dioxane (1 : 1), r.t. (11 h); (g)TBAF (3.3 equiv), THF (r.t., 14 h).
N
O
N
O
HO
N
O
NH
N
HO
I
Et EtEt
EtEtEt
O
OEt
NH
N
OH
NHH
a
b c
d
eg f
OTBS OTBS OTBS
OTBSOTBSOTBS
+
102
101
(80%)
CO2Et CO2Et
103
(73%)
104
(85%)
105
(98%)
106
(77%)
N3
107
H2N
108
(78% ⇒ 107)
(+/−)-Goniomitine (1)
Scheme 14: Reagents and conditions: (a) (i) NaI (1.5 equiv), TMSCl (1.5 equiv), MeCN (r.t., 30min), (ii) lactone 101 (1.0 equiv), MeCN (r.t.,16 h), (iii) TMSCl (0.5 equiv), EtOH (r.t., 71 h); (b) compound 102 (1.0 equiv), norbornene (2.01 equiv), K
2
CO3
(4.01 equiv), iodide 103 (4.01equiv), PdCl
2
(0.1 equiv), DMF-DMSO (9 : 1), H2
O (0.5mol L−1), air (60∘C, 26 h); (c) (i) indole 104 (1.0 equiv), LiHMDS (3.0 equiv), THF(−78∘C to r.t.), (ii) CH
2
=CHCH2
Br (3.0 equiv) (−78∘C (40min), r.t. (30min)); (d) (i) lactam 105 (1.0 equiv), 9-BBN (1.39 equiv), (0∘C (15min),r.t. (1 h)), (ii) aq. NaOH (1mol L−1), 35% aq. H
2
O2
(0.18mol L−1), 0∘C (30min); (e) alcohol 106 (1.0 equiv), PPh3
(2.08 equiv), DPPA (2.94equiv), DIAD (2.8 equiv), 0∘C to r.t. (3.5 h); (f) azide 107 (1.0 equiv), LiAlH
4
(4.01 equiv), THF (0∘C to r.t., 2 h); (g) AcOH-THF-H2
O (3 : 1 : 1,v/v), 40∘C (24 h).
-
ISRN Organic Chemistry 13
NH
N
H N
CHO
NH
HO
N
NH
HO
OH
N
NH
H
OH
N
NH
H
OH
N
NH
H
OH
a b
16
c
d
CO2Me
CO2Me CO2Me CO2Me
CO2Me
(−)-Vincadifformine (2)
5 steps(22%)
40 41
(79% ⇒ 40)
109
(71%)
110: C16-H𝛼111: C16-H𝛽 (4 : 1)
(90%)
(+)-Goniomitine (1)
Scheme 15: Reagents and conditions: (a) compound 40 (1.0 equiv), NaBH3
CN (5.73 equiv), AcOH (r.t., 2.5 h); (b) TiCl3
(3.1 equiv), MeOH(r.t., 20 h); (c) compound 109 (1.0 equiv), HCO
2
NH4
(5.71 equiv), 10% Pd-C (0.33 equiv), MeOH (reflux, 45min); (d) 4mol L−1 HCl (100∘C,1 h).
Cl OH
OO
OEt
OTf
OBn
COOMe
OBn
COOK
COOMe
OBnOH
OBn
N
OR
NHH
c
d g
hi
j
+
112 113 114
a-b(60%)
OTBS OTBS(80%)
115
(70%)
NO2
NO2NO2
NO2NO2
118
119
e-f(91%)
117116
(93%)
(72%)
N3
120
(80%)
121: R = Bn(+/−)-1: R = H
(65%)
Scheme 16: Reagents and conditions: (a) (i) compound 113 (2.0 equiv), CH3
MgCl (2.0 equiv), THF (−78∘C to r.t.), (ii) Mg (2.2 equiv), reflux(3 h), (iii) compound 112 (1.0 equiv), THF (reflux, 2 h), (iv) 2mol L−1HCl (0∘C, 3 h); (b) TBSCl (1.1 equiv), imidazole (1.5 equiv), DMF (r.t, 3 h);(c) (i) CuBr⋅Me
2
S (2.0 equiv), EtMgBr (4.0 equiv), THF (−78 to−40∘C, 40min), (ii) compound 114 (1.0 equiv), THF (−40∘C, 3 h), (iii) Comins’reagent (2.0 equiv), THF (r.t., 24 h); (d) compound 116 (1.0 equiv), ICH
2
CH2
OBn (1.2 equiv), Cs2
CO3
(1.3 equiv), DMF (60∘C, overnight);(e) compound 117 (1.0 equiv), 10% aq. KOH, MeOH-THF (5 : 1), r.t. (5-6 h); (f) t-BuOK (1.0 equiv), EtOH (r.t., 1 h); (g) (i) compound 118(1.2 equiv), [PdCl(allyl)]
2
(5mol%), X-Phos (15mol%), triflate 115 (1.0 equiv), diglyme (100∘C, 2 h), (ii) TBAF (4.0 equiv), THF (r.t., 4 h); (h)compound 119 (1.0 equiv), Ph
3
P (2.1 equiv), DPPA (2.9 equiv), DIAD (2.8 equiv), THF (0∘C to r.t., 3.5 h); (i) (i) compound 120 (1.0 equiv),NaHCO
3
(5.0 equiv), MeOH, O3
(−78∘C, 20–30 seg), (ii) Me2
S (50 equiv), −78∘C to r.t. (24 h), (iii) Zn (70 equiv), CaCl2
(20 equiv), MeOH(reflux, 2 h); (j) compound 121 (1.0 equiv), sodium naphthalenide (6.0 equiv), THF (−20∘C, 15min).
-
14 ISRN Organic Chemistry
References
[1] J. E. Saxton, “Recent progress in the chemistry of the monoter-penoid indole alkaloids,”Natural Product Reports, vol. 14, no. 6,pp. 559–590, 1997.
[2] M. El-Sayed and R. Verpoorte, “Catharanthus terpenoid indolealkaloids: biosynthesis and regulation,” Phytochemistry Reviews,vol. 6, no. 2-3, pp. 277–305, 2007.
[3] M. Frederich, M. Tits, and L. Angenot, “Potential antimalarialactivity of indole alkaloids,” Transactions of the Royal Society ofTropical Medicine and Hygiene, vol. 102, no. 1, pp. 11–19, 2008.
[4] J. Ziegler and P. J. Facchini, “Alkaloid biosynthesis: metabolismand trafficking,”Annual Review of Plant Biology, vol. 59, pp. 735–769, 2008.
[5] J. Háj́ıcek, “Recent developments in syntheses of the post-secodine indole alkaloids. Part III: rearranged alkaloid types,”Collection of Czechoslovak Chemical Communications, vol. 76,no. 12, pp. 2023–2083, 2011.
[6] L. Randriambola, J.-C. Quirion, C. Kan-Fan, and H.-P. Husson,“Structure of goniomitine, a new type of indole alkaloid,”Tetrahedron Letters, vol. 28, no. 19, pp. 2123–2126, 1987.
[7] C. Hashimoto and H.-P. Husson, “Synthetic and structuralstudies in the goniomitine alkaloid series: a new reductivecyclization reaction in the indole field,” Tetrahedron Letters, vol.29, no. 36, pp. 4563–4566, 1988.
[8] S. Takano, T. Sato, K. Inomata, and K. Ogasawara, “Theenantiocontrolled total synthesis of natural (-)-goniomitine,”Journal of the Chemical Society, Chemical Communications, no.7, pp. 462–464, 1991.
[9] G. Lewin, C. Schaeffer, and P. H. Lambert, “New rearrangementof an Aspidosperma alkaloid: the first biomimetic entry in thegoniomitine skeleton,” The Journal of Organic Chemistry, vol.60, no. 11, pp. 3282–3287, 1995.
[10] G. Lewin and C. Schaeffer, “Semisynthesis of (+)-(16S,20S, 21R)-16-hydroxymethyl-goniomitine from (−) vincad-ifformine,” Natural Product Letters, vol. 7, no. 3, pp. 227–234,1995.
[11] C. F. Gürtler, E. Steckhan, and S. Blechert, “[4 + 2]-cycloaddition reactions between 𝛽-acceptor-substituted enam-ines and 2-vinylindole radical cations acting as hetero-dienes,”The Journal of Organic Chemistry, vol. 61, no. 12, pp. 4136–4143,1996.
[12] J. C. F. Alves, Proposal of enantioselective synthesis of the indolealkaloid (-)-goniomitine and stereoisomers, [Qualification Examof Doctorate], NPPN, Universidade Federal do Rio de Janeiro,Rio de Janeiro, Brazil, 2000.
[13] G. Lewin, C. Schaeffer, R. Hocquemiller et al., “Access to newcytotoxic bisindole alkaloids by a modified Borch reductiveamination process,” Heterocycles, vol. 53, no. 11, pp. 2353–2356,2000.
[14] R. F. Borch, M. D. Bernstein, and H. D. Durst, “The cyanohy-dridoborate anion as a selective reducing agent,” Journal of theAmerican Chemical Society, vol. 93, no. 12, pp. 2897–2904, 1971.
[15] G. Lewin and C. Schaeffer, “One-pot access to 2,3-disubstituted1,2,3,4-tetrahydroquinolines by reductive amination of aldehy-des with sodium cyanoborohydride,”Heterocycles, vol. 48, no. 1,pp. 171–174, 1998.
[16] M. Raoul, C. Schaeffer, S. Léonce et al., “Synthesis of a novelseries of cytotoxic bisindole alkaloids,” Bioorganic & MedicinalChemistry Letters, vol. 11, no. 1, pp. 79–81, 2001.
[17] C. L. Morales and B. L. Pagenkopf, “Total synthesis of (±)-goniomitine via a formal nitrile/donor-acceptor cyclopropane
[3 + 2] cyclization,” Organic Letters, vol. 10, no. 2, pp. 157–159,2008.
[18] F. de Simone, J. Gertsch, and J. Waser, “Catalytic selectivecyclizations of aminocyclopropanes: formal synthesis of aspi-dospermidine and total synthesis of goniomitine,” AngewandteChemie International Edition, vol. 49, no. 33, pp. 5767–5770,2010.
[19] F. De Simone, J. Gertsch, and J. Waser, “Corrigendum: catalyticselective cyclizations of aminocyclopropanes: formal synthesisof aspidospermidine and total synthesis of goniomitine,” Ange-wandte Chemie International Edition, vol. 50, no. 18, p. 4038,2011.
[20] F. De Simone and J. Waser, “Cyclization of aminocyclo-propanes in indole alkaloids synthesis,” Synlett, no. 5, Article IDP00710ST, pp. 589–593, 2011.
[21] M. Mizutani, F. Inagaki, T. Nakanishi, C. Yanagihara, I. Tamai,and C. Mukai, “Total syntheses of (−)- and (+)-goniomitine,”Organic Letters, vol. 13, no. 7, pp. 1796–1799, 2011.
[22] C. Mukai and Y. Takahashi, “A new entry to the synthesis of 2,3-disubstituted indoles,” Organic Letters, vol. 7, no. 26, pp. 5793–5796, 2005.
[23] L. Jiao, E. Herdtweck, and T. Bach, “Pd(II)-catalysed regios-elective 2-alkylation of indoles via a norbornene-mediatedC-H activation: mechanism and applications,” Journal of theAmerican Chemical Society, vol. 134, no. 35, pp. 14563–14572,2012.
[24] L. Jiao and T. Bach, “Palladium-catalyzed direct 2-alkylationof indoles by norbornene-mediated regioselective cascade C-Hactivation,” Journal of the American Chemical Society, vol. 133,no. 33, pp. 12990–12993, 2011.
[25] G. Lewin, G. Bernadat, G. Aubert, and T. Cresteil, “Semisyn-thesis of (+)- and (−)-goniomitine from (−)- and (+)-vincadifformine,”Tetrahedron, vol. 69, no. 5, pp. 1622–1627, 2013.
[26] Z. Xu, Q. Wang, and J. Zhu, “Palladium-catalyzed decarboxyla-tive vinylation of potassium nitrophenyl acetate: application tothe total synthesis of (+/−)-goniomitine,” Angewandte ChemieInternational Edition, vol. 52, no. 11, pp. 3272–3276, 2013.
-
Submit your manuscripts athttp://www.hindawi.com
Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014
Inorganic ChemistryInternational Journal of
Hindawi Publishing Corporation http://www.hindawi.com Volume 2014
International Journal ofPhotoenergy
Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014
Carbohydrate Chemistry
International Journal of
Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014
Journal of
Chemistry
Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014
Advances in
Physical Chemistry
Hindawi Publishing Corporationhttp://www.hindawi.com
Analytical Methods in Chemistry
Journal of
Volume 2014
Bioinorganic Chemistry and ApplicationsHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014
SpectroscopyInternational Journal of
Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014
The Scientific World JournalHindawi Publishing Corporation http://www.hindawi.com Volume 2014
Medicinal ChemistryInternational Journal of
Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014
Chromatography Research International
Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014
Applied ChemistryJournal of
Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014
Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014
Theoretical ChemistryJournal of
Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014
Journal of
Spectroscopy
Analytical ChemistryInternational Journal of
Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014
Journal of
Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014
Quantum Chemistry
Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014
Organic Chemistry International
ElectrochemistryInternational Journal of
Hindawi Publishing Corporation http://www.hindawi.com Volume 2014
Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014
CatalystsJournal of